Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This opinion piece highlights the complex etiology of dilated cardiomyopathy and advocates for a precision medicine approach incorporating detailed phenotyping and genotyping to guide individualized therapy and risk stratification.
The current definition of dilated cardiomyopathy (DCM) is relatively simple; namely, a heart muscle disease characterized by left ventricular (LV) or biventricular dilation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.1 In the last decades, the prognosis of patients with DCM has improved significantly with survival free from death and heart transplantation rising to more than 80% at 8-year follow-up.2 This improvement in outcomes reflects the implementation of pharmacological and non-pharmacological therapeutic strategies, earlier diagnosis due to familial and sport-related screening, and individualized long-term follow-up with continuous restratification of risk. Despite the relatively benign natural history overall, clinical management of patients and families with DCM is still challenging. Dilated cardiomyopathy is currently the second most common heart failure phenotype and indication for heart transplantation, after ischaemic heart disease.3 In fact, a non-negligible proportion of DCM patients still have an unfavourable prognosis, particularly in the short-term, with substantial heart failure and arrhythmia-related risks. One reason for this is the complex and heterogeneous aetiology of the disease.4 Dilated cardiomyopathy is an ‘umbrella’ term that describes the final common pathway of different pathogenic processes and gene–environment interactions. There are many examples of Mendelian genetic disorders causing DCM, and it is probable that an individual genetic predisposition favours a dilated phenotype in the presence of trigger factors, such as inflammation, toxic insults from alcohol or drugs, and tachyarrhythmias. Dilated cardiomyopathy is also a feature of systemic disorders (i.e. autoimmune, endocrine, neuromuscular or infectious diseases, iron overload, sarcoidosis) that may be overlooked or diagnosed late in the course of disease. Distinguishing this complex aetiological diversity is likely to result in better prognostic stratification and ultimately targeted therapy. A thorough phenotyping and genotyping of DCM patients, through modern imaging techniques, such as speckle tracking echocardiography, cardiac magnetic resonance imaging, including a comprehensive tissue characterization analysis, and genetic testing on either selected gene panels or whole exome, represent the basis for the clinical management, but by themselves are often insufficient to define the aetiology. This requires better understanding of the complex interactions between environmental factors and genetic background, still an important gap of knowledge requiring focused research. A detailed aetiological characterization of newly diagnosed DCM is crucial for clinical management aiming to improve outcomes of DCM patients, through the following different strategies: Specific treatments and possible prognostic benefit derived from precise diagnosis of dilated cardiomyopathy. Note the possible application of precision medicine in genetically determined dilated cardiomyopathys, to be implemented in the next future. DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block. Arrhythmic risk stratification: Dilated cardiomyopathy patients are generally young (i.e. onset in 3rd to 5th decade of life) and barely symptomatic at diagnosis, thanks to early diagnosis due to systematic familial and sport activity screening programmes. In these patients, the burden of life-threatening ventricular arrhythmias is particularly high in comparison to heart failure-related events. Therefore, arrhythmic risk stratification remains challenging. The monoparametric current risk stratification model, essentially based on severely depressed left ventricular ejection fraction, appears inadequate and an individualized multiparametric evaluation is warranted. Tissue characterization through a comprehensive cardiac magnetic study including late gadolinium enhancement presence and localization is emerging as a fundamental tool other than clinical parameters, electrocardiogram, Holter monitoring, and echocardiographic findings.3 , 4 Furthermore, the prognostic relevance of gene mutations in the setting of familial DCM is emerging. With the advent of next-generation sequencing, the evidence that DCM is a genetic disease in a proportion of cases has strengthened13 and large cohort studies are establishing important genotype–phenotype correlations. Beyond the widely known LMNA mutations, recently other genes (e.g. FLNC, PLN, DSP, or RBM20) have been related to arrhythmic phenotypes, in so-called arrhythmogenic cardiomyopathy.14–17 Mutations in the gene encoding titin appear to be most frequent and are associated with an arrhythmic phenotype and a particular susceptibility to environmental stressors.18 Aetiological treatments: The definition of the precise genetic pathogenesis in many patients has shed light on the molecular mechanisms causing DCM and has stimulated research into new treatments that directly target gene expression or the downstream pathways that mediate the disease.19 Concurrently, advances have been made in the development of small molecules that can modulate the biophysical consequences of mutant proteins.20 Despite gaps in knowledge, precision medicine in cardiology is no longer a theoretical vision, but a realistic opportunity for the future treatment of patients with DCM (Figure 1). The movement from symptomatic to treatments targeting specific disease mechanisms represents a conceptual shift from slowing disease progression to a paradigm of disease reversal or prevention as the main objective. A novel approach to DCM patients, including a comprehensive evaluation, from the identification of possible removal environmental triggers to the identification of likely pathogenic genetic variants, should be promoted in order to apply individualized therapeutic strategies. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology. We are grateful to Dr Giulia De Angelis for her graphic support in performing the figure and Dr Antonio Cannatà for his support in editing the final version of the manuscript. Conflict of interest: none declared.
No takes yet. Share an insight, caveat, or question.
Sinagra et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: